Coronary restenosis

Summary

Coronary restenosis (MONDO:0005355) is a disease with 3 cohort genes (1 GWAS associations across 1 studies) and 71 clinical trials. Top therapeutic interventions include clopidogrel, sirolimus, and aspirin.

At a glance

• Cohort genes: 3
• GWAS associations: 1
• Clinical trials: 71

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	coronary restenosis
Mondo ID	MONDO:0005355
EFO	EFO:0004224
MeSH	D023903
DOID	DOID:4247
UMLS	C0948480
MedGen	182688
Is cancer (heuristic)	no

Data availability: 1 GWAS association (1 study).

Disease family

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › coronary artery disorder › coronary stenosis › coronary restenosis

Genetics & variants

GWAS landscape

1 GWAS associations across 1 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs10861032	1e-07	C12orf42 - LINC02401	C

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST001214	Sampietro ML	2011	295	0	A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
non_coding_transcript_exon_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs10861032	12	103518728	T>C,G	0.05	non_coding_transcript_exon_variant	C12orf42 - LINC02401	1e-07	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
STAB2	HGNC:18629	ENSG00000136011	Q8WWQ8	Stabilin-2	gwas
C12orf42	HGNC:24729	ENSG00000179088	Q96LP6	Uncharacterized protein C12orf42	gwas
NT5DC3	HGNC:30826	ENSG00000111696	Q86UY8	5’-nucleotidase domain-containing protein 3	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
STAB2	Stabilin-2	Phosphatidylserine receptor that enhances the engulfment of apoptotic cells.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	3	1.8×	0.174

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
STAB2	Other/Unknown	no		Link_dom, EGF, FAS1_domain
C12orf42	Other/Unknown	no		DUF4607
NT5DC3	Other/Unknown	no		HAD-SF_hydro_IG_5-nucl, Pur_nucleotidase, HAD_sf

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
liver	1
right lobe of liver	1
spleen	1
left testis	1
right testis	1
sperm	1
lower esophagus	1
lower esophagus muscularis layer	1
muscle layer of sigmoid colon	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
STAB2	164	tissue_specific	marker	spleen, right lobe of liver, liver
C12orf42	123	tissue_specific	marker	sperm, left testis, right testis
NT5DC3	198	ubiquitous	marker	muscle layer of sigmoid colon, lower esophagus muscularis layer, lower esophagus

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
STAB2	894
NT5DC3	483
C12orf42	189

Structural data

PDB: 1 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
STAB2	Q8WWQ8	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
NT5DC3	Q86UY8	87.18
C12orf42	Q96LP6	44.43

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 8. Enrichment computed across 3 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Scavenging by Class H Receptors	1	2855.0×	0.003	STAB2
Hyaluronan metabolism	1	951.7×	0.004	STAB2
Hyaluronan degradation	1	713.8×	0.004	STAB2
Binding and Uptake of Ligands by Scavenger Receptors	1	543.8×	0.004	STAB2
Glycosaminoglycan metabolism	1	219.6×	0.007	STAB2
Metabolism of carbohydrates and carbohydrate derivatives	1	120.2×	0.011	STAB2
Vesicle-mediated transport	1	34.8×	0.033	STAB2
Metabolism	1	11.6×	0.086	STAB2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
hyaluronan catabolic process	1	991.3×	0.007	STAB2
receptor-mediated endocytosis	1	221.7×	0.015	STAB2
defense response to Gram-positive bacterium	1	127.7×	0.015	STAB2
defense response to bacterium	1	108.0×	0.015	STAB2
endocytosis	1	95.2×	0.015	STAB2
angiogenesis	1	62.4×	0.019	STAB2
cell adhesion	1	37.5×	0.027	STAB2

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Everolimus	Phase 3

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 3

Druggability breadth: 0 of 3 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
STAB2	0	0
C12orf42	0	0
NT5DC3	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	3	STAB2, C12orf42, NT5DC3

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
STAB2	0	—
C12orf42	0	—
NT5DC3	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 71.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	40
PHASE4	14
PHASE3	6
PHASE1/PHASE2	4
PHASE2	4
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00162357	PHASE4	COMPLETED	Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
NCT00402272	PHASE4	COMPLETED	SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe
NCT00500279	PHASE4	UNKNOWN	Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial
NCT00552669	PHASE4	COMPLETED	Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents
NCT00714545	PHASE4	COMPLETED	SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents
NCT00752362	PHASE4	COMPLETED	Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT)
NCT00859183	PHASE4	COMPLETED	Oral Sirolimus for In-Stent Restenosis
NCT01066650	PHASE4	COMPLETED	The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente
NCT01106534	PHASE4	COMPLETED	XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
NCT01171820	PHASE4	COMPLETED	SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)
NCT01178268	PHASE4	COMPLETED	XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
NCT01331707	PHASE4	COMPLETED	DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population
NCT01967199	PHASE4	TERMINATED	Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis
NCT02300454	PHASE4	UNKNOWN	Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions
NCT00055510	PHASE2/PHASE3	COMPLETED	A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.
NCT00148356	PHASE2/PHASE3	COMPLETED	Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
NCT00180310	PHASE3	COMPLETED	SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
NCT00287573	PHASE2/PHASE3	COMPLETED	Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis
NCT00376870	PHASE3	UNKNOWN	PIoglitazone for PrEvention of Restenosis in Diabetic Patients
NCT00426049	PHASE3	UNKNOWN	Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
NCT00882219	PHASE3	COMPLETED	Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period
NCT00916370	PHASE3	COMPLETED	SPIRIT PRIME Clinical Trial
NCT03667313	PHASE3	COMPLETED	Treatment of In-Stent Restenosis 2 Study
NCT00106587	PHASE1/PHASE2	COMPLETED	Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR I)
NCT00124943	PHASE1/PHASE2	COMPLETED	Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
NCT00140101	PHASE2	COMPLETED	Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
NCT00243308	PHASE2	TERMINATED	Serp-1 for the Treatment of Acute Coronary Syndrome
NCT00248066	PHASE2	COMPLETED	Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries
NCT00409981	PHASE1/PHASE2	COMPLETED	Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II)
NCT01269242	PHASE2	COMPLETED	The Effects of Bindarit in Preventing Stent Restenosis
NCT01274234	PHASE1/PHASE2	COMPLETED	OCT Evaluation of Healing of COMBO Stent
NCT04280029	Not specified	ACTIVE_NOT_RECRUITING	SELUTION SLR™ 014 In-stent Restenosis
NCT04988685	Not specified	RECRUITING	SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters
NCT06075602	Not specified	RECRUITING	COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease
NCT07239921	Not specified	NOT_YET_RECRUITING	Disease Characteristics of R-CAD
NCT00180466	Not specified	COMPLETED	PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions
NCT00300131	Not specified	COMPLETED	ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation
NCT00412126	Not specified	COMPLETED	Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI
NCT00589810	Not specified	COMPLETED	Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal
NCT00631228	Not specified	COMPLETED	XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLOPIDOGREL	4	3
SIROLIMUS	4	2
ASPIRIN	4	1
CELECOXIB	4	1
EVEROLIMUS	4	1
SERINE	3	1
TECHNETIUM	3	1
BINDARIT	2	1
BO-653	2	1
CHEMBL5282669	0	1
CHEMBL4079877	0	1
CHEMBL4525833	0	1